OrbiMed Capital GP VII LLC (CIK 1760648) reported 19 SEC Form 4 insider transactions across 4 companies over the past 18 months (most recent 2026-06-24). Recent activity: Sell ELVN (24,846 shares), Sell ELVN (1,477 shares), Sell ELVN (787,024 shares), Sell ELVN (46,776 shares), Sell ELVN (9,086 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 24,846 | $1.1M |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 1,477 | $66,465 |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 787,024 | $35.7M |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 46,776 | $2.1M |
| 2026-06-17 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 9,086 | $409,052 |
| 2026-06-17 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 272,322 | $12.3M |
| 2026-06-01 | Q32 Bio Inc. (QTTB) | Director | Buy | 1.2M | $10.0M |
| 2026-06-01 | Q32 Bio Inc. (QTTB) | Director | Buy | 625,000 | $5.0M |
| 2025-12-18 | Keros Therapeutics, Inc. (KROS) | Director | Sell | 140,057 | $2.5M |
| 2025-12-18 | Keros Therapeutics, Inc. (KROS) | Director | Sell | 74,465 | $1.3M |
| 2025-06-26 | Passage BIO, Inc. (PASG) | Insider | Sell | 231,600 | $81,060 |
| 2025-06-26 | Passage BIO, Inc. (PASG) | Insider | Sell | 138,800 | $45,804 |
| 2025-06-26 | Passage BIO, Inc. (PASG) | Insider | Sell | 213,257 | $70,375 |
| 2025-04-24 | Passage BIO, Inc. (PASG) | Insider | Sell | 78,049 | $26,537 |
| 2025-04-24 | Passage BIO, Inc. (PASG) | Insider | Sell | 89,328 | $30,372 |
| 2025-04-24 | Passage BIO, Inc. (PASG) | Insider | Sell | 68,195 | $21,822 |
| 2025-04-17 | Passage BIO, Inc. (PASG) | Insider | Sell | 10,326 | $3,924 |
| 2025-04-17 | Passage BIO, Inc. (PASG) | Insider | Sell | 61,638 | $20,341 |
| 2025-04-17 | Passage BIO, Inc. (PASG) | Insider | Sell | 77,090 | $25,440 |
Source: SEC Form 4 filings · as of 2026-06-24